Sign in Subscribe
Immunotherapy

KRAS Mutations in Non-Small-Cell Lung Cancer: Impact on Disease Phenotype and Survival Outcomes

Strategic Insights

— 1 min read

Researchers at the Curie Institute in Paris, France have conducted a retrospective analysis of a large database of lung cancer patients to investigate the impact of KRAS mutations on disease phenotype and survival outcomes. The study found that patients with KRAS mutations were more likely to be smokers and had a higher proportion of programmed death-ligand 1 (PD-L1) positivity. Furthermore, the study showed that patients with KRAS p.G12C mutations had better survival outcomes compared to those with KRAS non-p.G12C mutations.

Key Takeaways:

  • The RAS/MEK signaling pathway is essential in carcinogenesis and frequently altered in non-small-cell lung cancer (NSCLC), with KRAS mutations affecting 25%-30% of non-squamous NSCLC.
  • The study included 10,177 patients with advanced or metastatic lung cancer from the French Epidemiological Strategy and Medical Economics database, with 17.6% having KRAS p.G12C mutations, 22.6% having KRAS non-p.G12C mutations, and 59.8% being KRAS wild-type.
  • Patients with KRAS mutations were more likely to be smokers (96.3%) compared to KRAS wild-type patients (85.8%).
  • A higher proportion of PD-L1 positivity was found for KRAS mutated patients: 43.5% versus 38.0% (P < 0.001).
  • Patients with KRAS p.G12C mutations had better survival outcomes compared to those with KRAS non-p.G12C mutations.
  • Further research on the impact of emerging KRAS specific inhibitors is warranted in real-world cohorts.

Statistics:

  • 25%-30% of non-squamous NSCLC patients had KRAS mutations.
  • 17,600 patients (17.6%) had KRAS p.G12C mutations.
  • 22,600 patients (22.6%) had KRAS non-p.G12C mutations.
  • 59,800 patients (59.8%) were KRAS wild-type.
  • 96.3% of patients with KRAS mutations were smokers.
  • 43.5% of patients with KRAS mutations were PD-L1 positive.
  • 38.0% of patients without KRAS mutations were PD-L1 positive.

Sources:

  • NewsRx. Findings in the Area of Immunotherapy Reported from Curie Institute (Clinical Characteristic and Survival Outcomes of Patients With Advanced Nsclc According To kras Mutational Status In the French Real-life Esme Cohort). Immunotherapy Weekly. September 18, 2024; p 1365.
  • ESMO Open, 2024;9(6). ESMO Open can be contacted at: Elsevier, Radarweg 29, 1043 Nx Amsterdam, Netherlands.

Read more